# Mechanisms underlying the role of TNF-α and IL-1β preconditioned exosomes derived from human umbilical cord mesenchymal stem cells in wound healing

**Authors:** Ziyue Zhou, Rui Cao, Lei Shi, Wenhu Jin

PMC · DOI: 10.3389/fimmu.2026.1713004 · Frontiers in Immunology · 2026-02-17

## TL;DR

This study shows that exosomes from stem cells preconditioned with TNF-α and IL-1β improve wound healing by boosting collagen and blood vessel formation.

## Contribution

The study identifies miR-215-5p as a key miRNA in preconditioned exosomes that enhances wound healing via the WNK1/p-Smad3/VEGF-A pathway.

## Key findings

- TNF-α+IL-1β-Exos accelerated wound healing more than conventional exosomes.
- miR-215-5p promotes HUVEC tubulogenesis and proliferation in vitro and wound healing in vivo.
- miR-215-5p activates the WNK1/p-Smad3/VEGF-A signaling axis to enhance angiogenesis.

## Abstract

In this study, human umbilical cord mesenchymal stem cells (hUC-MSCs) were stimulated with tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) to obtain preconditioned exosomes (Exos). Comparative miRNA profiling was performed between cytokine-primed Exos and conventionally cultured counterparts to identify differentially expressed miRNAs. Functional validation of candidate miRNAs will elucidate their mechanistic roles in promoting cutaneous repair, thereby advancing the clinical translation of Exos-based regenerative therapies.

We successfully extracted and characterized hUC-MSCs derived Exos (hUCMSCs-Exos) and classified them into Exos obtained under normal culture conditions (Con-Exos) and those stimulated by TNF-α+IL-1β obtained Exos (TNF-α+IL-1β-Exos). The wound healing rate was observed and counted by establishing a mouse whole skin defect wound model in vivo. In vitro, human umbilical vein endothelial cells (HUVECs) were stimulated with two groups of hUCMSCs-Exos to observe the tube formation of HUVECs and the results of 5-ethynyl-2’-deoxyuridine (EdU) assay.Then, the differential miRNAs in the two groups of hUCMSCs-Exos were detected and validated to identify the candidate effector miRNAs, which were then analyzed by databases and searched and screened for common target genes.

TNF-α+IL-1β-Exos accelerated wound healing more than Con-Exos, mainly by increasing collagen deposition and expression of the angiogenic marker CD31. Sequencing and bioinformatics analyses revealed that the key miRNA for both co-actions was miR-215-5p. Cellular experiments showed that miR-215-5p mimics promoted HUVECs tubulogenesis and proliferation, whereas the inhibitor effect was not significant. In animal experiments, miR-215-5p mimics also significantly accelerated wound healing in mice.

TNF-α+IL-1β-Exos demonstrated superior wound healing efficacy compared to Con-Exos. This enhanced therapeutic effect may be attributed to the elevated expression of miR-215-5p in TNF-α+IL-1β-Exos. Mechanistically, miR-215-5p activates the WNK1/p-Smad3/VEGF-A signaling axis, promoting angiogenesis and accelerating cutaneous wound repair.

## Linked entities

- **Genes:** WNK1 (WNK lysine deficient protein kinase 1) [NCBI Gene 65125], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422]
- **Proteins:** PECAM1 (platelet and endothelial cell adhesion molecule 1)
- **Chemicals:** 5-ethynyl-2’-deoxyuridine (PubChem CID 472172)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Tsg101 (tumor susceptibility gene 101) [NCBI Gene 22088] {aka CC2}, Pecam1 (platelet/endothelial cell adhesion molecule 1) [NCBI Gene 18613] {aka Cd31, PECAM-1, Pecam}, Pik3r2 (phosphoinositide-3-kinase regulatory subunit 2) [NCBI Gene 18709] {aka p85beta}, SMAD3 (SMAD family member 3) [NCBI Gene 4088] {aka HSPC193, HsT17436, JV15-2, LDS1C, LDS3, MADH3}, WNK1 (WNK lysine deficient protein kinase 1) [NCBI Gene 65125] {aka HSAN2, HSN2, KDP, PPP1R167, PRKWNK1, PSK}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Cd9 (CD9 antigen) [NCBI Gene 12527] {aka Tspan29}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, ZEB2 (zinc finger E-box binding homeobox 2) [NCBI Gene 9839] {aka HSPC082, SIP-1, SIP1, SMADIP1, ZFHX1B}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, ITGB1 (integrin subunit beta 1) [NCBI Gene 3688] {aka CD29, FNRB, GPIIA, MDF2, MSK12, VLA-BETA}, Cd81 (CD81 antigen) [NCBI Gene 12520] {aka Tapa-1, Tapa1, Tspan28}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Vcam1 (vascular cell adhesion molecule 1) [NCBI Gene 22329] {aka CD106, Vcam-1}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CD34 (CD34 molecule) [NCBI Gene 947], Irak1 (interleukin-1 receptor-associated kinase 1) [NCBI Gene 16179] {aka IRAK, IRAK-1, IRAK1-S, IRAK1b, Il1rak, Plpk}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Cd63 (CD63 antigen) [NCBI Gene 12512] {aka ME491, Tspan30}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Mir215 (microRNA 215) [NCBI Gene 387211] {aka Mirn215, mir-215, mmu-mir-215}, Tmt1a (thiol methyltransferase 1A1) [NCBI Gene 70152] {aka 2210414H16Rik, 3300001H21Rik, Aam-B, Mettl7a, Mettl7a1, UbiE1}, XIAP (X-linked inhibitor of apoptosis) [NCBI Gene 331] {aka API3, BIRC4, IAP-3, ILP1, MIHA, XLP2}, Smad3 (SMAD family member 3) [NCBI Gene 17127] {aka Madh3}, Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 12767] {aka CD184, CXC-R4, CXCR-4, Cmkar4, LESTR, PB-CKR}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 22339] {aka L-VEGF, Vegf, Vpf}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, Pten (phosphatase and tensin homolog) [NCBI Gene 19211] {aka 2310035O07Rik, A130070J02Rik, B430203M17Rik, MMAC1, PTENbeta, TEP1}, PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175] {aka CD31, CD31/EndoCAM, GPIIA', PECA1, PECAM-1, endoCAM}, Wnk1 (WNK lysine deficient protein kinase 1) [NCBI Gene 232341] {aka 6430573H23Rik, EG406236, Hsn2, Prkwnk1, mKIAA0344}, Canx (calnexin) [NCBI Gene 12330] {aka 1110069N15Rik, Cnx, D11Ertd153e}
- **Diseases:** hepatocellular carcinoma (MESH:D006528), necrotic (MESH:D009336), skin defect (MESH:D012868), chronic (MESH:D002908), metastasis (MESH:D009362), hypoxia (MESH:D000860), inflammation (MESH:D007249), wounds (MESH:D014947), tumor (MESH:D009369), diabetic (MESH:D003920)
- **Chemicals:** citrate (MESH:D019343), CO2 (MESH:D002245), paraformaldehyde (MESH:C003043), PBS (MESH:D007854), Tween (MESH:D011136), DAB (MESH:C000469), PVDF (MESH:C024865), DAPI (MESH:C007293), CY5 (MESH:C085321), Opti-MEM (-), hydrogen peroxide (MESH:D006861), H&amp;E (MESH:D006371), melatonin (MESH:D008550), hematoxylin (MESH:D006416), PKH26 (MESH:C070080), isoflurane (MESH:D007530), TRIzol (MESH:C411644), TSA (MESH:C481298), 5-ethynyl-2'-deoxyuridine (MESH:C031086), SDS (MESH:D012967), paraffin (MESH:D010232), Methanol (MESH:D000432), oxygen (MESH:D010100), Triton X-100 (MESH:D017830)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953127/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953127/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953127/full.md

---
Source: https://tomesphere.com/paper/PMC12953127